{"schema_version":"secwatch.filing_event.v1","accession":"0001827090-23-000008","form_type":"8-K","ticker":"CERT","cik":"0001827090","company_name":"Certara, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.523323+00:00","generated_at":"2026-06-11T23:14:32.035557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Certara Q2 revenue $90.5M, net income $4.7M; lowers FY2023 outlook","bullets":["Revenue $90.5M (+9% YoY, +10% constant currency); net income $4.7M vs loss $0.6M.","Adjusted EBITDA $32.4M (+16% YoY); software revenue and bookings each +17% YoY.","Services revenue +5% YoY but bookings declined; CEO cites cautious spending by small biotech.","Software renewal rate 93% in Q2; management expects services demand improvement in 2024.","FY2023 full-year guidance reduced due to lower services growth and slow regulatory recovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001827090-23-000008","json":"https://secwatch.observer/filing/0001827090-23-000008.json","markdown":"https://secwatch.observer/filing/0001827090-23-000008.md","text":"https://secwatch.observer/filing/0001827090-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827090/000182709023000008/0001827090-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827090/000182709023000008/certara-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:14:32.035557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20dfa11605e9d2e32676432c65a2d3f9ce71916f","claim":"Certara, Inc. reported the second quarter of fiscal year 2023 results: revenue $90.5 million, net income $4.7 million. Guidance reaffirmed.","evidence_excerpt":"Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. Second Quarter Highlights: • Revenue was $90.5 million, compared to $82.8 million in the second quarter of 2022, representing growth of 9% over the second quarter of 2022 on a reported basis and 10% at constant currency. • Net income","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827090/000182709023000008/0001827090-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of fiscal year 2023"},{"label":"Revenue","value":"$90.5 million"},{"label":"Net income","value":"$4.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}